MORPHINE HP 25 - 25MG/ML SOLUTION

Страна: Канада

Език: английски

Източник: Health Canada

Активна съставка:

MORPHINE SULFATE

Предлага се от:

SANDOZ CANADA INCORPORATED

АТС код:

N02AA01

INN (Международно Name):

MORPHINE

дозиране:

25MG

Лекарствена форма:

SOLUTION

Композиция:

MORPHINE SULFATE 25MG

Начин на приложение:

INTRAMUSCULAR

Броя в опаковка:

1/4ML

Вид предписание :

Narcotic (CDSA I)

Терапевтична област:

OPIATE AGONISTS

Каталог на резюме:

Active ingredient group (AIG) number: 0104545005; AHFS:

Статус Оторизация:

CANCELLED POST MARKET

Дата Оторизация:

2023-07-28

Данни за продукта

PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
MORPHINE HP 25
Morphine sulfate injection USP
25 mg/mL
MORPHINE HP 50
Morphine sulfate injection USP
50 mg/mL
Narcotic Analgesic
Sandoz Canada Inc.
110 rue de Lauzon
Date of Revision: May 17, 2019
Boucherville, QC, Canada
J4B 1E6
Submission Control No: 221205
_Morphine HP 25 / Morphine HP 50_
_Page 2 of 31 _
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
......................................................... 3
SUMMARY PRODUCT INFORMATION
.......................................................................
3
INDICATIONS AND CLINICAL USE
.............................................................................
3
CONTRAINDICATIONS
..................................................................................................
3
WARNINGS AND PRECAUTIONS
.................................................................................
4
ADVERSE REACTIONS
.................................................................................................
12
DRUG INTERACTIONS
.................................................................................................
14
DOSAGE AND ADMINISTRATION
.............................................................................
15
OVERDOSAGE
...............................................................................................................
19
ACTION AND CLINICAL PHARMACOLOGY
........................................................... 20
STORAGE AND STABILITY
.........................................................................................
21
SPECIAL HANDLING INSTRUCTIONS
......................................................................
21
DOSAGE FORMS, COMPOSITION AND PACKAGING
............................................ 21
PART II: SCIENTIFIC INFORMATION
...............................................................................
23
REFERENCES
.................................................................................................................
23
PART